ABOS
Acumen Pharmaceuticals Inc

1,102
Loading...
Loading...
News
all
press releases
Acumen Pharmaceuticals Earnings Preview
read more...
Benzinga·10mo ago
News Placeholder
More News
News Placeholder
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Expected to Earn Q2 2024 Earnings of ($0.26) Per Share
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2024 EPS estimates for shares of Acumen Pharmaceuticals in a note issued to...
Zolmax·1y ago
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) vs. Inhibrx (NASDAQ:INBX) Head-To-Head Analysis
Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) and Inhibrx (NASDAQ:INBX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two...
Zolmax·1y ago
News Placeholder
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 1,020,000 shares, an...
Zolmax·1y ago
News Placeholder
HC Wainwright Weighs in on Acumen Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:ABOS)
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS Free Report) Equities research analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Acumen Pharmaceuticals...
Zolmax·1y ago
News Placeholder
Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?
Investors might want to bet on Acumen Pharmaceuticals, Inc. (ABOS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates...
Zacks Investment Research·1y ago
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Rating Reaffirmed by HC Wainwright
Acumen Pharmaceuticals (NASDAQ:ABOS Get Free Report)s stock had its buy rating restated by investment analysts at HC Wainwright in a research report issued to clients and...
Ticker Report·1y ago
News Placeholder
Q4 2023 Acumen Pharmaceuticals Inc Earnings Call Transcript
Related Stocks: NAS:ABOS...
GuruFocus·1y ago
News Placeholder
Acumen Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
Acumen Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation...
SeekingAlpha·1y ago
News Placeholder
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
Initiation of a Phase 2 study, ALTITUDE-AD, to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease expected in the first half of 2024 Initiation of a Phase 1 study to...
Globe Newswire·1y ago

Latest ABOS News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.